{"protocolSection":{"identificationModule":{"nctId":"NCT06944379","orgStudyIdInfo":{"id":"ORKA-002-211"},"organization":{"fullName":"Oruka Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose","officialTitle":"Phase 1, First-in-human, Double-blind, Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Healthy Participants"},"statusModule":{"statusVerifiedDate":"2025-09","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-05-19","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2027-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-04-15","studyFirstSubmitQcDate":"2025-04-23","studyFirstPostDateStruct":{"date":"2025-04-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-25","lastUpdatePostDateStruct":{"date":"2025-09-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Oruka Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is a Phase 1, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of ORKA-002 in healthy participants.","detailedDescription":"This is a single center, Phase 1, double-blind, placebo-controlled, randomized, first-in-human (FIH), single ascending dose study evaluating the safety, tolerability, pharmacokinetics (PK) of ORKA-002 in healthy volunteers. The study will enroll approximately 24 healthy volunteers. The ORKA-002 dose will be administered by a subcutaneous injection."},"conditionsModule":{"conditions":["Healthy Volunteers"],"keywords":["ORKA-002","Phase 1"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"OTHER","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":24,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"ORKA-002","type":"EXPERIMENTAL","description":"Subcutaneous (SC) injection of ORKA-002","interventionNames":["Drug: ORKA-002"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Subcutaneous (SC) injection of placebo comparator","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"ORKA-002","description":"ORKA-002 is supplied as sterile solution to be administered by SC injection","armGroupLabels":["ORKA-002"]},{"type":"OTHER","name":"Placebo","description":"Placebo solution to be administered at a matching volume by SC injection","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of Treatment-emergent Adverse Events","description":"Incidence of treatment-emergent adverse events and clinically significant changes from baseline in vital signs, electrocardiograms, and clinical laboratory parameters","timeFrame":"Day 1 through 1 year"}],"secondaryOutcomes":[{"measure":"Maximum observed serum concentration of ORKA-002","description":"Cmax of ORKA-002","timeFrame":"Day 1 through 1 year"},{"measure":"Time to Cmax (Tmax) of ORKA-002","description":"Tmax of ORKA-002","timeFrame":"Day 1 through 1 year"},{"measure":"Area under the serum concentration-time curve (AUC) of ORKA-002","description":"Area under the curve from the time of dosing to infinity (AUC0-inf)","timeFrame":"Day 1 through 1 year"},{"measure":"Terminal elimination half-life (T1/2)","description":"T1/2 of ORKA-002","timeFrame":"Day 1 through 1 year"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n1. Healthy male or female participants\n2. 18 to 65 years (inclusive) with a body mass index (BMI) 18 to 32 kg/m2 at Screening\n3. Willing and able to remain at the study site unit for the duration of the confinement period and return for the outpatient visit(s)/s defined in the protocol\n4. Using two methods of contraception (one being highly effective) from admission through the end of the study\n\nKey Exclusion Criteria:\n\n1. Any clinically significant medical condition or finding that, in the Investigator's opinion, is likely to unfavorably alter the risk of study participation, confound study results, or interfere with the study conduct or compliance.\n2. Known history of illicit drug use or drug abuse or harmful alcohol use\n3. Known history of frequent tobacco or vaping use within 2 years prior to screening\n4. Unwilling to abstain from regular, continuous alcohol use or tobacco use as per protocol\n5. History of severe allergic reactions or hypersensitivity\n6. Actively nursing, lactating, pregnant, or plans to be pregnant\n7. Use of any investigational drug therapy within 30 days prior to enrollment\n8. Unable to comply with study requirements or in the opinion of the Investigator should not participate in this study","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Kyle Breitschwerdt","affiliation":"Oruka Therapeutics, Inc.","role":"STUDY_DIRECTOR"},{"name":"Principal Investigator","affiliation":"Oruka Therapeutics Investigative Site","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Oruka Therapeutics Investigative Site","city":"Christchurch","state":"New Zealand","country":"New Zealand","geoPoint":{"lat":-43.53333,"lon":172.63333}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"}},"hasResults":false}